|
1. |
Analysis of Whole Blood Tacrolimus Concentrations in Liver Transplant Patients Exhibiting Impaired Liver Function |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 585-585
Gordon MacFarlane,
Leslie Shaw,
Raman Venkataramanan,
Richard Mullins,
Daniel Scheller,
Diana Ersfeld,
Preview
|
|
摘要:
SummaryIn transplant patients with impaired liver function, HPLC methodologies have been suggested for monitoring whole blood tacrolimus concentrations because of the reported inaccuracy of immunoassay for whole blood tacrolimus concentrations. One hundred fifty whole blood samples from 50 subjects enrolled in a multicenter liver transplant trial were chosen for HPLC/MS/MS analysis without consideration of the clinical status of the patient at the time of sampling. These samples were chosen to represent the sampling intervals during the 12-week posttransplantation period. Retrospectively, the authors identified a subset of 39 samples from 27 subjects exhibiting impaired liver function as demonstrated by bilirubin concentrations > 3.0 mg/dL (mean ± SD = 7.5 ± 5.6 mg/dL). The authors compared the agreement of concentrations obtained from the PRO-Trac II ELISA and HPLC/MS/MS by least squares linear regression analysis and Bland/Altman analysis, in this subset against the agreement of concentrations for 76 samples with normal bilirubin. In the samples obtained from patients with impaired liver function the resulting regression equation was: ELISA = 1.19(HPLC) + 0.7;r= 0.9. The mean difference (HPLC/MS/MS − ELISA) was −2.5 ng/mL ± 2.9 ng/mL (mean ± SD). While 71% of samples agreed within 3 ng/mL, 3% (n = 1) exhibited a difference >10 ng/ml. The corresponding evaluation of the samples with normal bilirubin concentrations resulted in the regression equation ELISA = 0.96(HPLC) + 0.9;r= 0.9, and a mean difference of −0.6 ng/mL ± 2.3 ng/mL. The authors conclude that while a small subset of patients with cholestasis may require closer evaluation with a more specific methodology, the majority of the patients may be satisfactorily monitored with the PRO-Trac II ELISA.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
2. |
Report on Intrauterine Drug Exposure During Second Trimester of Pregnancy in a Heroin-Associated Death |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 593-593
Lucia Pötsch,
Gisela Skopp,
Patricia Emmerich,
Jürgen Becker,
Sylvester Ogbuhui,
Preview
|
|
摘要:
SummaryA 17-year-old girl was found dead in a public toilet with fresh needle puncture marks. She was 18–20 weeks pregnant with a male fetus. Drug screening of her blood and urine indicated recent heroin use. Chronic drug use was confirmed by hair analysis. Amniotic fluid as well as fetal and maternal tissues and body fluids were analyzed by GC/MS and HPLC. All the fetal specimens were investigated, and the following levels of drugs were found: 6-monoacetyl-morphine (blood: 152 ng/g; amniotic fluid: 128 ng/g; brain: 140 ng/g; lung: 110 ng/g; liver: 2 ng/g; kidney: 40 ng/g), morphine (blood: 1360 ng/g; amniotic fluid: 604 ng/g; brain: 710 ng/g; lung: 1030 ng/g; liver: 2060 ng/g; kidney: 1100 ng/g), codeine (blood: 70 ng/g; brain: 60 ng/g; lung: 60 ng/g; liver: 90 ng/g; kidney: 70 ng/g), and morphine-3-glucuronide (amniotic fluid: 209 ng/g; brain: 170 ng/g; lung: 325 ng/g; kidney: 231 ng/g). Morphine-6-glucuronide was present in the maternal circulation but could not be detected in the fetal circulation.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
3. |
The Pharmacokinetics of Theophylline in Premature Neonates During the First Few Days After Birth |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 598-598
Marie du Preez,
Julia Botha,
M. McFadyen,
Nick Holford,
Preview
|
|
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
4. |
Effect of Felbamate on Clobazam and Its Metabolite Kinetics in Patients With Epilepsy |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 604-604
Manuela Contin,
Roberto Riva,
Fiorenzo Albani,
Agostino Baruzzi,
Preview
|
|
摘要:
SummaryThe authors report preliminary findings on the effect of the new generation antiepileptic drug (AED) felbamate (FBM) on steady state plasma concentrations of clobazam (CLB), a benzodiazepine (frequently used as add-on therapy in patients with refractory epilepsy) and its active metabolite n-desmethyl-clobazam (N-CLB). The authors prospectively collected plasma samples from 66 children and adults with epilepsy receiving chronic CLB therapy. On the basis of concomitant AEDs, patients were divided into three subgroups otherwise comparable for age and weight-adjusted daily dose of CLB: group A (n = 22), receiving CLB monotherapy or CLB plus AEDs without inducing properties of cytochrome P450 (CYP) metabolism, namely valproic acid (VPA) or lamotrigine (LTG); group B (n = 28), receiving CLB plus AED inducer polytherapy (carbamazepine, phenobarbital, phenytoin), even associated with VPA (n = 9) or LTG (n = 12); group C (n = 16), receiving CLB plus FBM, associated with AED inducers, VPA or LTG. Level to weight-adjusted dose ratio (L/D) of CLB in groups B and C was twofold lower compared to group A (p < 0.001). L/D of N-CLB was twofold higher in group B and fivefold in group C compared to group A (p < 0.001). The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001). These data confirm previous reports of a significant increase in CLB clearance in patients receiving AED inducers, leading to an accumulation of its main metabolite. They also provide novel evidence of a further marked increase in N-CLB plasma concentrations in patients receiving FBM cotherapy. From a clinical point of view, this finding should be kept in mind in explaining possible toxicity in patients on complex AED polytherapy. Furthermore, knowledge of the in vivo interaction between CLB and FBM could help in identifying the CYP isoforms involved in the metabolism of both CLB and N-CLB.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
5. |
A Reversed-Phase High-Performance Liquid Chromatography Method for the Determination of Cotrimoxazole (Trimethoprim/ Sulphamethoxazole) in Children Treated for Malaria |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 609-609
Anita Rønn,
Theonest Mutabingwa,
Solveigh Kreisby,
Helle Angelo,
Kurt Fuursted,
Ib Bygbjerg,
Preview
|
|
摘要:
SummaryA high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of trimethoprim (TMP), sulphamethoxazole (SMX), and acetylsulphamethoxazole (AcSMX) in small amounts of blood. The method involved precipitation with 50 &mgr;L trichloracetic acid (1M) to 125 &mgr;L plasma or serum sample. 60 &mgr;L supernatant was added to 60 &mgr;L mobile phase, modified with 50 &mgr;L 1 M sodium hydroxide/mL. The mobile phase consisted of 20% acetonitrile and 80% phosphate buffer adjusted to pH 6.15. Using 125 &mgr;L of the sample, limits of quantitation were 0.1 &mgr;g/mL for TMP, 1.0 &mgr;g/mL for SMX, and 1.0 &mgr;g/mL for AcSMX. The precision of the method was 2% to 11% over the range of concentrations tested, 0.5–30 &mgr;g/mL for TMP, 5–300 &mgr;g/mL for SMX, and 2.5–150 &mgr;g/mL for AcSMX, respectively. No interference with other commonly used drugs was observed. The method is rapid, simple, specific, and sensitive enough for pharmacokinetic studies. The small amount of blood required makes it suitable for pediatric patients. The method was used to analyze samples from Tanzanian children aged 6–59 months participating in a cotrimoxazole (TMP/SMX)/chloroquine randomized trial for the treatment of uncomplicated malaria. Venous blood samples from 68 children were collected 2 hours after the first dose of TMP/SMX (4 mg/kg TMP/20 mg/kg SMX at two divided doses for 5 days) and again at treatment day 4. Individual variations in plasma concentrations of TMP, SMX, and AcSMX were considerable. The mean and SEM plasma concentrations (g/mL) of TMP, SMX, and AcSMX 2 hours after the first treatment dose were 2.0 ± 1.0 (range 0.5–6), 53 ± 22 (range 24–146), and 13.5 ± 12 (range 0–65), respectively. On the fourth day the attained plasma concentrations were not significantly different from samples collected after the first dose.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
6. |
A Case of Sustained Massive Gabapentin Overdose Without Serious Side Effects |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 615-615
Amit Verma,
E. St Clair,
Rodney Radtke,
Preview
|
|
摘要:
SummaryGabapentin is an antiepileptic agent that is indicated for use as adjunctive therapy for partial seizures. It has a relatively benign side effect profile, but little data exists on massive overdoses with this agent. The authors present a case of a patient who received a massive overdose of this agent but suffered no clinically significant toxicity.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
7. |
Can Tobramycin Inhalation Be Improved With a Jet Nebulizer? |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 618-618
Paul Le Brun,
Alexander Vinks,
Daan Touw,
Nicole Hekelaar,
Gregor Mannes,
Roland Brimicombe,
Erik Frijlink,
Harry Heijerman,
Preview
|
|
摘要:
SummaryData on the pharmacokinetics of antibiotics after inhalation are limited. The aim of this pilot study was to assess the pharmacokinetics of tobramycin under optimalized and standardized aerosol circumstances and, furthermore, to be able to consider possible treatment of exacerbations with inhalation therapy. Six patients were studied after inhalation of 600 mg tobramycin. A jet nebulizer loaded with a 10% solution of tobramycin in water was used. The percentage of the dose that was systemically absorbed ranged from 1.0% to 16.6%. The maximum serum levels of tobramycin ranged from 0.77 mg/L to 3.63 mg/L (mean 1.70 ± 1.01). The pharmacokinetic data were best described by a two-compartment model. Compared to intravenous administration, the long terminal half-life (mean 9.47 h ± 3.28 h) could be explained by the slow absorption of tobramycin from the site of administration (flip-flop model). Despite standardized aerosol conditions, considerable interpatient variability was observed. However, the relatively low serum levels allow a further increase of the dose.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
8. |
Sensitive Methods for Determination of Free Digitoxin Concentration Using Digitoxin Immunoassays: Demonstration of Elevated Free Digitoxin Concentration Caused by Digitoxin–Phenytoin Interaction by Applying These New Techniques |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 625-625
Amitava Dasgupta,
Anita Vega,
Alice Wells,
Pradip Datta,
Preview
|
|
摘要:
SummaryDigitoxin is very strongly bound to serum albumin. Although free digitoxin is pharmacologically active, it is not monitored because of the lack of a sufficiently sensitive technique. The concentration of free digitoxin in the protein-free ultrafiltrate is usually below the detection limit of digitoxin immunoassays. A modified technique is described by which free digitoxin can be routinely monitored using commercially available immunoassays. The fluorescence polarization immunoassay for determining total digitoxin concentration requires that 100 &mgr;L of serum be treated with 300 &mgr;L of methanol to precipitate proteins. It is demonstrated that free digitoxin can easily be measured by adding 100 &mgr;L of methanol to 300 &mgr;L of ultrafiltrate, thus improving the sensitivity of the assay three-fold. The free digitoxin concentration can easily be calculated by dividing the observed value by 3. An attempt to use only ultrafiltrate (no methanol added) caused significant bias in the result, probably as a result of a matrix problem. The chemiluminescent assay for digitoxin does not require any specimen pretreatment and requires only 10 &mgr;L of serum. The program was modified and used 50 &mgr;L of ultrafiltrate to improve the sensitivity of the free digitoxin assay. If the chemiluminescent assay is used to measure free digitoxin, the true free digitoxin concentration can be calculated by dividing the observed value by 4.3. The free digitoxin concentrations were comparable in eight patients receiving digitoxin as measured by both methods. To show an application of this technique, two serum pools were prepared from patients receiving digitoxin and supplemented with various concentrations of phenytoin. A significant increase in free digitoxin concentration was observed because of the displacement of digitoxin from protein binding sites by phenytoin.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
9. |
Determination of Platinum Complexes in Clinical Samples by a Rapid Flameless Atomic Absorption Spectrometry Assay |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 631-631
Charlotte Kloft,
Helge Appelius,
Wolfgang Siegert,
Walter Schunack,
Ulrich Jaehde,
Preview
|
|
摘要:
SummaryThe frequent use of platinum (Pt) complexes in cancer chemotherapy and the application of new therapeutic options and dosing strategies have increased the need for rapid analytic procedures to determine Pt concentrations in the biologic fluids of patients. Therefore a flameless atomic absorption spectrometry method for the quantification of Pt in plasma and ultrafiltrate was developed and validated. A simple sample preparation of only one dilution step was established. Only 400 &mgr;L of whole blood was required for duplicate analysis of Pt in both matrices. The matrix-specific temperature programs took less than 75 seconds. The lower limit of quantification was 40 ng Pt/mL and 20 ng Pt/mL for plasma and ultrafiltrate, respectively. Suitable linearity could be reached using separate calibration curves for the high and low Pt concentration ranges. Recovery of Pt was complete, and there were no major stability problems. The accuracy and precision of the new method met the international criteria for the validation of bioanalytic methods. In addition, the use of different anticoagulants for clinical sampling, ultrafiltration systems, and ultrafiltration conditions were investigated. The assay has already been extensively applied to pharmacokinetic studies. In conclusion, the new Pt assay proved to be rapid, simple, sensitive, and suitable for clinical use.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
10. |
Evaluation of the EMIT Mycophenolic Acid Assay From Dade Behring |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 6,
1999,
Page 638-638
Mariette Vogl,
Günter Weigel,
Gernot Seebacher,
Andrea Griesmacher,
Güter Laufer,
Mathias Müller,
Preview
|
|
摘要:
SummaryThe Emit Mycophenolic Acid Assay, a new homogeneous enzyme immunoassay for the quantitative analysis of mycophenolic acid (MPA) in human plasma, was evaluated and compared to a high-performance liquid chromatography (HPLC) method. Coefficients of variation (CV) of the within-run imprecision (n = 10) varied from 2.5% to 4.4% and from 1.3% to 4.9% for the Emit and the HPLC, respectively. The CV's of between-day imprecision (n = 10) ranged from 7.9% to 10.8% for the Emit and from 4.7% to 12.1% for the HPLC. Mean recoveries were 95.6% and 100.1% for Emit and HPLC, respectively. Serial dilution of a patient pool demonstrated a linear relationship between expected (x) and measured (y) concentrations: Emit,y= 0.998x+ 0.086; HPLC,y= 1.006x− 0.016. The detection limit and the lower limit of quantification were 0.087 mg/L and 0.20 mg/L for Emit. The detection limit for HPLC was 0.08 mg/L using a signal-to-noise ratio of three. Sample stability under various storage conditions was satisfactory, although storage at −20°C is recommended for storage longer than one day. No cross-reactivity from the major metabolite mycophenolic acid glucuronide (MPAG) was found. A correlation study on 261 patient samples yielded the following regression equation (bivariate Deming procedure): Emit = 1.012HPLC + 0.244,r= 0.970.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
|